0.91% More Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shorted Shares

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Corporate Logo

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) had an increase of its shares shorted by 0.91%. In April was published LXRX’s total 8.00 million shares shorted by FINRA. That’s 0.91% up from 7.93 million shares. With Average volume 537,100, LXRX’s previous position will take 15 days to recover. Lexicon Pharmaceuticals Inc’s shares shorted float is 7.58%.

Ticker’s shares touched $5.65 during the last trading session after 4.07% change.Currently Lexicon Pharmaceuticals, Inc. is downtrending after 20.39% change in last April 17, 2018. LXRX has also 260,552 shares volume. LXRX underperformed the S&P500 by 24.76%.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases.The company has $600.44 million market cap. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults.Currently it has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage

A total of 3 analysts rate Lexicon Pharmaceuticals (NASDAQ:LXRX) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:LXRX) has 10 ratings reports on Apr 17, 2019 according to StockzIntelligence. On Monday, March 25 Stifel Nicolaus maintained Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with “Buy” rating. On Friday, November 2 the stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Buy” rating given by Citigroup. On Monday, March 25 the rating was maintained by Wedbush with “Buy”. On Thursday, March 14 Gabelli downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to “Sell” rating. On Friday, March 15 the firm has “Buy” rating given by Wedbush. On Monday, March 4 the company was maintained by Wedbush.

For more Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news posted briefly go to: Seekingalpha.com, Nasdaq.com, Benzinga.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Lexicon down 29% on FDA rejection of sotagliflozin – Seeking Alpha” posted on March 22, 2019, “Lexicon Pharmaceuticals to Present at Upcoming Investor Conference – Nasdaq” on April 02, 2019, “41 Stocks Moving In Monday’s Mid-Day Session – Benzinga” with a publish date: March 25, 2019, “60 Biggest Movers From Friday – Benzinga” and the last “Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know – Nasdaq” with publication date: February 21, 2019.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.